Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 2
1979 2
1981 2
1982 2
1983 2
1985 2
1986 4
1987 4
1988 1
1989 2
1990 4
1991 5
1992 6
1993 11
1994 9
1995 12
1996 8
1997 9
1998 9
1999 8
2000 13
2001 13
2002 10
2003 9
2004 11
2005 11
2006 15
2007 7
2008 7
2009 11
2010 10
2011 13
2012 9
2013 9
2014 20
2015 14
2016 17
2017 13
2018 16
2019 13
2020 8
2021 12
2022 11
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Primary Bone Lymphoma"
Page 1
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ. Ollila TA, et al. Curr Treat Options Oncol. 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. Curr Treat Options Oncol. 2018. PMID: 29931605 Free PMC article. Review.
Its prognosis and risk of recurrence in the central nervous system (CNS) vary according to the primary site of origin. ...Radiation therapy also appears to be associated with better progression-free survival in primary bone DLBCL. Future studies …
Its prognosis and risk of recurrence in the central nervous system (CNS) vary according to the primary site of origin. …
The epidemiology of osteosarcoma.
Ottaviani G, Jaffe N. Ottaviani G, et al. Cancer Treat Res. 2009;152:3-13. doi: 10.1007/978-1-4419-0284-9_1. Cancer Treat Res. 2009. PMID: 20213383 Review.
Osteosarcoma derives from primitive bone-forming mesenchymal cells and is the most common primary bone malignancy. ...Other likely locations are the skull or jaw (8%) and the pelvis (8%). Cancer deaths due to bone and joint malignant neoplasms represen …
Osteosarcoma derives from primitive bone-forming mesenchymal cells and is the most common primary bone malignancy. ...O …
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel tar …
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has re …
Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F, Dogan A, Cook JR. Fend F, et al. Virchows Arch. 2023 Jan;482(1):163-177. doi: 10.1007/s00428-022-03431-3. Epub 2022 Nov 21. Virchows Arch. 2023. PMID: 36414803 Free PMC article. Review.
For diagnosis of localized plasma cell tumors, solitary plasmacytoma of bone, and primary extraosseous plasmacytoma, the importance of excluding minimal bone marrow infiltration by flow cytometry is emphasized. ...Multiple myeloma is subdivided into 4 mutuall …
For diagnosis of localized plasma cell tumors, solitary plasmacytoma of bone, and primary extraosseous plasmacytoma, the impor …
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain MD, Subklewe M. Rejeski K, et al. Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543. Blood. 2021. PMID: 34166502 Free PMC article.
In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers in 258 patients receiving axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for relapsed/refractory large B-cell lymphoma. ... …
In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers in 258 p …
Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.
Quintanilla-Martinez L, Laurent C, Soma L, Ng SB, Climent F, Ondrejka SL, Zamo A, Wotherspoon A, de Leval L, Dirnhofer S, Leoncini L. Quintanilla-Martinez L, et al. Virchows Arch. 2023 Sep;483(3):281-298. doi: 10.1007/s00428-023-03590-x. Epub 2023 Aug 9. Virchows Arch. 2023. PMID: 37555980 Free PMC article. Review.
LBCL-IRF4 has an excellent prognosis, with distinguishing molecular findings. IRF4 rearrangements, although characteristic of this entity, are not specific and can be found in association with other chromosomal translocations in other large B-cell lymphomas. Other m …
LBCL-IRF4 has an excellent prognosis, with distinguishing molecular findings. IRF4 rearrangements, although characteristic of this en …
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH. Armand P, et al. Blood. 2023 Sep 7;142(10):878-886. doi: 10.1182/blood.2022019386. Blood. 2023. PMID: 37319435 Free PMC article.
Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durabi …
Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with …
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Brüggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Topp MS, et al. Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16. Lancet Oncol. 2015. PMID: 25524800 Clinical Trial.
BACKGROUND: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19, an antigen consistently expressed on B-lineage acute lymphoblastic leukae …
BACKGROUND: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab …
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, Hartley JA, Spanswick V, Lowe H, Popova B, Clifton-Hadley L, Wheeler G, Olejnik J, Bloor A, Irvine D, Wood L, Marzolini MAV, Domning S, Farzaneh F, Lowdell MW, Linch DC, Pule MA, Peggs KS. Roddie C, et al. J Clin Oncol. 2021 Oct 20;39(30):3352-3363. doi: 10.1200/JCO.21.00917. Epub 2021 Aug 31. J Clin Oncol. 2021. PMID: 34464155 Free PMC article. Clinical Trial.
PURPOSE: Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. ...METHODS: Patients age 16 years with r/r B-ALL were eligible. Primary outcomes were toxicity an …
PURPOSE: Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric a …
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A, Arumov A, Schatz JH. Trabolsi A, et al. Blood Cancer J. 2024 Feb 8;14(1):27. doi: 10.1038/s41408-024-00997-w. Blood Cancer J. 2024. PMID: 38331870 Free PMC article. Review.
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. ...CD19-directed chimeric antigen receptor T-cell (CAR-19) t …
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still wil …
363 results